Media headlines about Inovio Pharmaceuticals (NASDAQ:INO) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.1529796779741 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Inovio Pharmaceuticals, Inc. (INO) Expected to Announce Quarterly Sales of $7.75 Million (americanbankingnews.com)
- Inovio Pharmaceuticals, Inc. (INO) is at $4.74 per share and Vertex Pharmaceuticals Incorporated (VRTX) is listed at … – Stocks Gallery (stocksgallery.com)
- Guide to Day Traders: Inovio Pharmaceuticals Inc (NASDAQ: INO) – Alpha Beta Stock (alphabetastock.com)
- Zacks Investment Research Downgrades Inovio Pharmaceuticals, Inc. (INO) to Sell (americanbankingnews.com)
- Inovio Pharmaceuticals, Inc. (INO) Downgraded to “Sell” at Zacks Investment Research (americanbankingnews.com)
Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at $4.31 on Wednesday. Inovio Pharmaceuticals has a one year low of $4.20 and a one year high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). The company had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The company’s revenue was down 79.2% compared to the same quarter last year. During the same period last year, the company posted ($0.28) earnings per share. equities analysts forecast that Inovio Pharmaceuticals will post -1.08 earnings per share for the current year.
The company also recently declared a monthly dividend, which was paid on Monday, October 16th. Shareholders of record on Friday, September 29th were issued a dividend of $0.069 per share. This represents a $0.83 dividend on an annualized basis and a yield of 19.21%. The ex-dividend date was Thursday, September 28th.
INO has been the topic of several recent analyst reports. Aegis reissued a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. Citigroup Inc. assumed coverage on Inovio Pharmaceuticals in a report on Friday, October 6th. They set a “buy” rating and a $10.00 target price for the company. BidaskClub lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. ValuEngine raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 11th. Finally, Royal Bank Of Canada assumed coverage on Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price objective for the company. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Inovio Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $19.16.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://weekherald.com/2017/11/15/inovio-pharmaceuticals-ino-earning-somewhat-positive-press-coverage-report-shows.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.